Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.81 |
| ▸ | HRH1 | P35367 | 1/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | HRH2 | P25021 | 1/20 | 0.74 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.71 |
| ▸ | LTA4H | P09960 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823877 | 1.00 | HRH3 (0.87) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| Bromide SCHEMBL23393414 | 0.98 | HRH3 (0.84) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL492205 | 0.98 | HRH3 (0.84) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL15920898 | 0.95 | HRH3 (0.82) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL7398556 | 0.93 | HRH3 (0.82) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL491556 | 0.93 | HRH3 (0.82) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL5291543 | 0.93 | HRH3 (0.82) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL492095 | 0.93 | HRH3 (0.82) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| SCHEMBL491672 | 0.93 | HRH3 (0.79) | HRH3KCNH2HRH1KDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL27731873 | 0.92 | KDM4E (0.97) | HRH3KCNH2HRH1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002100861-A1 | 1-(3-PHENYLOXYPROPYL)PIPERIDINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2002-12-19 | — | — | WO | claimed |
| EP-2776437-B1 | MODULATORS OF OPIOID RECEPTORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9708305-B2 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases | UNIVERSITé LAVAL (CA) | 2017-07-18 | — | — | US | disclosed |
| US-20160200685-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | UNIVERSITé LAVAL (CA) | 2016-07-14 | — | — | US | disclosed |
| EP-1874746-B1 | DERIVATIVES OF 1-N-AZACYCLOALKYL-3-PHENOXYPROPANE USEFUL FOR THE PREPARATION OF PSYCHOTROPIC MEDICAMENTS | BIOPROJET SOC CIV (FR) | 2015-11-18 | — | — | EP | disclosed |
| EP-1874746-B1 | DERIVATIVES OF 1-N-AZACYCLOALKYL-3-PHENOXYPROPANE USEFUL FOR THE PREPARATION OF PSYCHOTROPIC MEDICAMENTS | BIOPROJET SOC CIV (FR) | 2015-11-18 | — | — | EP | disclosed |
| WO-2015024111-A1 | COMPOUNDS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | UNIVERSITE LAVAL (CA) | 2015-02-26 | — | — | WO | disclosed |
| EP-1670460-B1 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2014170343-A1 | DEPOLARIZING AGENTS AND NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING DOPAMINERGIC-RELATED DISORDERS | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2014-10-23 | — | — | WO | disclosed |
| CN-101258138-B | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3-receptor ligands | BIOPROJET SOC CIV | 2013-06-12 | — | — | CN | disclosed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002100861-A1 | 1-(3-PHENYLOXYPROPYL)PIPERIDINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100861-A1 | 1-(3-PHENYLOXYPROPYL)PIPERIDINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100861-A1 | 1-(3-PHENYLOXYPROPYL)PIPERIDINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2002-12-19 | — | — | WO | disclosed |
| EP-1216244-A1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | Aventis Pharmaceuticals Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| CN-1292789-A | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AWANDIS PHARMACEUTICAL CORP (US) | 2001-04-25 | — | — | CN | disclosed |
| WO-2001019821-A1 | BENZISOXAZOLYL-, PYRIDOISOXAZOLYL- AND BENZTHIENYL-PHENOXY DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200685-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | STS, SHBG, CYP19A1 | HRH3 238/4885KCNH2 1486/4885HRH1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.